# Central Nervous System (CNS) Agents: Anti-Migraine Agents, Prophylaxis

## LENGTH OF AUTHORIZATIONS

Initial Authorization 180 days

 Subsequent Authorizations 365 days

## PRIOR AUTHORIZATION CRITERIA

- Is there any reason the patient cannot be changed to a medication not requiring prior approval?

    Acceptable reasons include:

  - Allergy to preferred medications
  - Contraindication to **three** preferred medications
  - History of unacceptable/toxic side effects/intolerance to at least **three** preferred medications

## STEP THERAPY REQUIRED PREFERRED MEDICATION

- For a drug requiring step therapy, there must have been inadequate clinical response to a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors).

## NON-PREFERRED MEDICATION

- For a non-preferred medication drug there must have been inadequate clinical response to a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors) AND an inadequate clinical response or intolerance to a trial of at least 30 days of one step therapy required preferred medication

## ADDITIONAL CRITERIA FOR MIGRAINE PROPHYLAXIS

1. Patient must have one of the following diagnoses:

   a. **Episodic** migraine with the following frequencies of migraine:
        - 4-15 headaches per 30 days measured over 90 consecutive days and headache duration of longer than 4 hours per day or longer during an attack on average.

   b. **Chronic** migraine with the following frequencies of migraine:
        - 15 or more headaches per 30 days measured over 90 consecutive days and headache duration of longer than 4 hours per day or longer during an attack on average

2. Prior Authorization may be approved if the patient has failed a trial of at least 30 days each to at least 3 controller migraine medications or has experienced contraindications or intolerance to them (i.e., beta-blockers, anticonvulsants, tricyclic antidepressants, and/or serotonin-norepinephrine reuptake inhibitors).
3. Initial authorization will be limited to 180 days. Re-authorization for 365 days will be allowed based upon evidence of improved headache control (such as headache diary or attestation of ongoing efficacy from provider).

\*Aimovig Initial Dose is limited to 70mg once per 30 days; may request dose increase if 70mg fails to provide adequate relief over 60 consecutive days.

\* Ajovy 675mg doses (quarterly administration) will not be authorized until patient has demonstrated efficacy of medication for at least 90 days.

## Anti-Migraine Agents, Prophylaxis

| Central Nervous System (CNS) Agents: Anti-Migraine Agents, Prophylaxis    |                |
|---------------------------------------------------------------------------|----------------|
| PREFERRED                                                                 | NON-PREFERRED  |
| Aimovig QL ST                                                             | Emgality       |
| Ajovy ST                                                                  | Nurtec ODT     |
| Cardiovascular Agents: Beta-Blockers                                      | Qulipta        |
| CNS Agents: Anticonvulsants                                               |                |
| CNS Agents: Serotonin-Norepinephrine Reuptake Inhibitors                  |                |
| CNS Agents: Tricyclic Antidepressants                                     |                |

### Link to Criteria

[Central Nervous System (CNS) Agents: Anti-Migraine Agents, Prophylaxis](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=24)
